Loading...
Loading...
Bank of America initiated its coverage on Merrimack Pharmaceuticals
MACK with a Buy rating and a price objective of $13 a share on the company's novel drug platform.
Bank of America noted, "Merrimack is a currently loss-making biotech company with an unusually large, early-stage oncology pipeline resulting from its unique “Network Biology” technology platform. Our Buy rating is based on our positive outlook for the first validation of MACK's technology expected in 1H13, when randomized P2 studies for the company and partner Sanofi-Aventis' cancer drug MM-121 report data. We are less enamored with MACK's most advanced drug MM-398, and do not view positive P3 data (mid 2014 est.) as core to our investment thesis."
Merrimack Pharmaceuticals closed at $7.55 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in